Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Teens with HIV: does inflammation harm thinking skills?

NCT ID NCT07165639

Knowledge-focused Sponsor: Eswatini Nazarene Health Institutions Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether inflammation from HIV affects thinking skills in teens aged 13-19 in Eswatini. Researchers will compare 50 HIV-positive teens on antiretroviral therapy with 30 HIV-negative teens. They will test memory, attention, and processing speed, and measure inflammation markers in blood. The goal is to understand the link between HIV, inflammation, and brain health in adolescents.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal how inflammation from HIV affects brain function in teens, pointing toward ways to protect their thinking skills.
What could go wrong
This is an observational study with only 80 participants, so results may not apply to all teens with HIV. It looks at links, not causes, and may not lead to treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will encompass all adolescents attending RFM hospitals, Baylor RFM, and Baylor Mbabane: 1. Adolescents aged 13 to 19 years who are on antiretroviral therapy (ART) and attending the Baylor clinic at RFM and Baylor Mbabane. 2. HIV-negative adolescents aged 13 to 19 years who meet the inclusion criteria and are consulting at the RFM hospital outpatient department.

Ages

13 to 19 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Cases * Adolescents aged 13-19 years * HIV-positive * Undergoing antiretroviral therapy at Baylor Clinic * Providing consent or assent to participate Controls * Adolescents aged 13-19 years * HIV-negative * Providing consent or assent to participate Exclusion Criteria: * Exclusion Criteria * Recent (within 2 months) acute conditions: influenza, COVID-19, TB, acute gastroenteritis (as these conditions elevate CRP levels) * Chronic conditions: diabetes, hypertension, asthma * Neurological disorders: epilepsy, cerebrovascular accident, neurodegenerative diseases * History of significant cranial trauma or perinatal complications * All the aforementioned conditions will be identified through self-reported data and medical records.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV (human immunodeficiency virus) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV (human immunodeficiency virus)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Eswatini Nazarene Health Institution, Baylor College of Medicine Children's Foundation-Eswatini (Centers of Excellence in Mbabane and satellite clinic in Manzini in Raleigh Fitkin Memorial Hospital)

    Manzini, M200, Eswatini

More trials for these conditions

Other studies related to the condition(s) this trial covers.